Patient Information

Dear Patient,

Your doctor has chosen a Medical Device by Regenlab to be used during your planned treatment. Your doctor will discuss the planned treatment plan, the mode of action and future risks and possible therapy options with you in detail in a private interview prior to the surgery. The purpose of this FAQs is to assist you for the interview and inform you about the characteristics of the medical device used.

This information should not replace the private discussion with your doctor.

Please refer to your Medical Device name below :

  • Cellular Matrix BCT-HA, Ref.: BCT-HA-1, BCT-HA-3


  • Cellular Matrix A-CP-HA, Ref.: A-CP-HA-1, A-CP-HA-3


  • ArthroVisc40, Ref.: ARV-HA40-1, ARV-HA40-3


Our products being approved under the Medical Device Regulation EU 2017/745, the patient information supports are currently being implemented. An implant card intended to be filled by the physician after the medical intervention and a patient leaflet will be soon supplied with the products mentioned above.


Our Regional offices are
located in

  • New York (USA)
  • Montréal (Canada)
  • Venice (Italy)
  • Munich (Germany)
  • Paris (France)
  • Dubai (U.A.E.)
  • Beijing (China)
  • and Istanbul (Turkiye)